Full Breakdown
UK Clinical Trial of Puberty Blockers Paused Over Safety Concerns
2/21/2026, 3:09:02 AM
Overview of the Clinical Trial
The Pathways clinical trial, aimed at investigating the effects of puberty blockers on children and young people experiencing gender incongruence, has been paused following concerns raised by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA recommended that the trial should establish a minimum age limit of 14 for participants due to the “unquantified risk” of long-term biological harms associated with the medication. Discussions between the MHRA and the trial sponsor, King’s College London, are set to begin next week to address these concerns.
Background and Context
The trial was initiated following the Cass Review, which evaluated children’s gender care and deemed the existing research on the benefits of puberty blockers as “poor.” In light of this review, NHS England had previously restricted the use of puberty blockers to research settings only, discontinuing their routine administration to children with gender dysphoria.
Official Statements & Responses
A spokesperson from the Department of Health and Social Care emphasized the importance of prioritizing the safety and wellbeing of children involved in the trial, stating, “This trial will only be allowed to go ahead if the expert scientific and clinical evidence and advice conclude it is both safe and necessary.” King’s College London reiterated its commitment to the health of young participants, asserting that the trial was designed with scientific rigor and that they would collaborate with the MHRA for further review.
Criticism & Opposition
The pause has drawn mixed reactions. Conservative leader Kemi Badenoch has called for the trial to be halted entirely, warning of potential harm to children. In contrast, Claire Coutinho, shadow equalities minister, described the pause as a “huge win,” suggesting that it reflects a necessary caution in the face of safety concerns. Sir Jonathan Montgomery, a professor of health care law, noted that the regulatory process is functioning as intended, focusing on safety rather than legal issues.
Conflicting Reports & Gaps
While the MHRA has called for the age limit to be raised to 14, the trial initially planned to recruit participants as young as 10 for biological females and 11 for biological males. The discrepancy between the proposed age limits and the MHRA's recommendations highlights ongoing debates about the appropriate age for administering puberty blockers.
Verbatim Quotes
- “The letter said: “Since potentially significant and, as yet, unquantified risk of long-term biological harms is present to participants and biological safety has not been definitively demonstrated in this proposed cohort, at the very least, there should be a graded/stepwise approach starting with those aged 14 as the lower limit of eligibility.” — MHRA Letter
- “A spokesperson for King’s College London said: “The wellbeing and health of young people with gender incongruence and their families has been, and will remain, our priority, and we will continue to work with the MHRA to support their further review of the trial, which has been designed by world-leading academics with scientific rigour at its core.” — King’s College London Spokesperson
- “The focus here is on safety, as it should be. This pause shows the regulatory process working properly and in the interests of participants.” — Sir Jonathan Montgomery, Professor of Health Care Law
The future of the Pathways clinical trial remains uncertain as discussions continue to address the MHRA's concerns, with recruitment on hold until a resolution is reached.
